Top

International Journal of Clinical Oncology

Published in:

01-08-2010 | Review Article

Clinicopathological features and treatment strategy for triple-negative breast cancer

Authors: Yutaka Yamamoto, Hirotaka Iwase

Published in: International Journal of Clinical Oncology | Issue 4/2010

Abstract

Breast cancers are divided into at least 4 subtypes on the basis of gene expression profiles and expression of receptors (hormone receptors (HR) and HER2) as measured by immunohistochemistry. These subtypes have different prognoses and responses to treatments such as endocrine manipulation, anti-HER2 therapy, and chemotherapy. Triple-negative breast cancer (TNBC) is immunohistochemically defined as lacking estrogen and progesterone receptors and not overexpressing HER2. TNBC accounts for approximately 15% of breast cancer patients, and is more chemosensitive but has a worse prognosis than the HR-positive/HER2-negative phenotype. TNBC is a heterogeneous disease that does not offer specific targets in the same way as HR-positive and HER2-positive breast cancers, and is similar to basal-like breast cancer and BRCA1-related breast cancer. At present, the lack of highly effective therapeutic targets for TNBC leaves standard chemotherapy, for example the combination of anthracycline and taxane, as the only medical treatment, but this is insufficiently efficacious. Novel approaches for TNBC, for example DNA damaging agents, PARP-1 inhibitors, receptor tyrosin kinase inhibitors (TKIs), and antiangiogenesis agents, have been examined in clinical settings. Concerning therapeutic strategies for TNBC, it is most important to develop novel effective approaches for TNBC treatment and high-throughput predictive tools for standard chemotherapy and novel agents.

Sorlie T, Perou CM, Tibshirani R et al (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98:10869–10874CrossRefPubMed

Bauer KR, Brown M, Cress RD et al (2007) Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. Cancer 109:1721–1728CrossRefPubMed

Cheang MC, Voduc D, Bajdik C et al (2008) Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res 14:1368–1376CrossRefPubMed

Kwan ML, Kushi LH, Weltzien E et al (2009) Epidemiology of breast cancer subtypes in two prospective cohort studies of breast cancer survivors. Breast Cancer Res 11:R31CrossRefPubMed

Rakha EA, El-Sayed ME, Green AR et al (2007) Prognostic markers in triple-negative breast cancer. Cancer 109:25–32CrossRefPubMed

Carey LA, Perou CM, Livasy CA et al (2006) Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 295:2492–2502CrossRefPubMed

Millikan RC, Newman B, Tse CK et al (2008) Epidemiology of basal-like breast cancer. Breast Cancer Res Treat 109:123–139CrossRefPubMed

Iwase H, Kurebayashi J, Tsuda H et al (2010) Clinicopathological analyses of triple negative breast cancer using surveillance data from the Registration Committee of the Japanese Breast Cancer Society. Breast Cancer 17:118–124CrossRefPubMed

Gluz O, Liedtke C, Gottschalk N et al (2009) Triple-negative breast cancer–current status and future directions. Ann Oncol 20:1913–1927CrossRefPubMed

10.

Schneider BP, Winer EP, Foulkes WD et al (2008) Triple-negative breast cancer: risk factors to potential targets. Clin Cancer Res 14:8010–8018CrossRefPubMed

11.

Hugh J, Hanson J, Cheang MC et al (2009) Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial. J Clin Oncol 27:1168–1176CrossRefPubMed

12.

Dent R, Trudeau M, Pritchard KI et al (2007) Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 13:4429–4434CrossRefPubMed

13.

Tischkowitz M, Brunet JS, Begin LR et al (2007) Use of immunohistochemical markers can refine prognosis in triple negative breast cancer. BMC Cancer 7:134CrossRefPubMed

14.

Fulford LG, Reis-Filho JS, Ryder K et al (2007) Basal-like grade III invasive ductal carcinoma of the breast: patterns of metastasis and long-term survival. Breast Cancer Res 9:R4CrossRefPubMed

15.

Dent R, Hanna WM, Trudeau M et al (2009) Pattern of metastatic spread in triple-negative breast cancer. Breast Cancer Res Treat 115:423–428CrossRefPubMed

16.

Fulford LG, Easton DF, Reis-Filho JS et al (2006) Specific morphological features predictive for the basal phenotype in grade 3 invasive ductal carcinoma of breast. Histopathology 49:22–34CrossRefPubMed

17.

Harris LN, Broadwater G, Lin NU et al (2006) Molecular subtypes of breast cancer in relation to paclitaxel response, outcomes in women with metastatic disease: results from CALGB 9342. Breast Cancer Res 8:R66CrossRefPubMed

18.

Freedman GM, Anderson PR, Li T et al (2009) Locoregional recurrence of triple-negative breast cancer after breast-conserving surgery and radiation. Cancer 115:946–951CrossRefPubMed

19.

Haffty BG, Yang Q, Reiss M et al (2006) Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol 24:5652–5657CrossRefPubMed

20.

Kyndi M, Sorensen FB, Knudsen H et al (2008) Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group. J Clin Oncol 26:1419–1426CrossRefPubMed

21.

Nguyen PL, Taghian AG, Katz MS et al (2008) Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy. J Clin Oncol 26:2373–2378CrossRefPubMed

22.

Voduc KD, Cheang MC, Tyldesley S et al (2010) Breast cancer subtypes and the risk of local and regional relapse. J Clin Oncol 28:1684–1691CrossRefPubMed

23.

Oakman C, Viale G, Di Leo A (2010) Management of triple negative breast cancer. Breast

24.

Rakha EA, Putti TC, Abd El-Rehim DM et al (2006) Morphological and immunophenotypic analysis of breast carcinomas with basal and myoepithelial differentiation. J Pathol 208:495–506CrossRefPubMed

25.

Thike AA, Cheok PY, Jara-Lazaro AR et al (2010) Triple-negative breast cancer: clinicopathological characteristics and relationship with basal-like breast cancer. Mod Pathol 23:123–133CrossRefPubMed

26.

Viale G, Bottiglieri L (2009) Pathological definition of triple negative breast cancer. Eur J Cancer 45(Suppl 1):5–10CrossRefPubMed

27.

Jung SY, Kim HY, Nam BH et al (2010) Worse prognosis of metaplastic breast cancer patients than other patients with triple-negative breast cancer. Breast Cancer Res Treat 120:627–637CrossRefPubMed

28.

Stockmans G, Deraedt K, Wildiers H et al (2008) Triple-negative breast cancer. Curr Opin Oncol 20:614–620CrossRefPubMed

29.

Honma N, Saji S, Kurabayashi R et al (2008) Oestrogen receptor-beta1 but not oestrogen receptor-betacx is of prognostic value in apocrine carcinoma of the breast. APMIS 116:923–930CrossRefPubMed

30.

Bidard FC, Conforti R, Boulet T et al (2007) Does triple-negative phenotype accurately identify basal-like tumour? An immunohistochemical analysis based on 143 ‘triple-negative’ breast cancers. Ann Oncol 18:1285–1286CrossRefPubMed

31.

Diaz LK, Cryns VL, Symmans WF et al (2007) Triple negative breast carcinoma and the basal phenotype: from expression profiling to clinical practice. Adv Anat Pathol 14:419–430CrossRefPubMed

32.

Irvin WJ Jr, Carey LA (2008) What is triple-negative breast cancer? Eur J Cancer 44:2799–2805CrossRefPubMed

33.

Kang SP, Martel M, Harris LN (2008) Triple negative breast cancer: current understanding of biology and treatment options. Curr Opin Obstet Gynecol 20:40–46CrossRefPubMed

34.

Kreike B, van Kouwenhove M, Horlings H et al (2007) Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas. Breast Cancer Res 9:R65CrossRefPubMed

35.

Lerma E, Peiro G, Ramon T et al (2007) Immunohistochemical heterogeneity of breast carcinomas negative for estrogen receptors, progesterone receptors and Her2/neu (basal-like breast carcinomas). Mod Pathol 20:1200–1207CrossRefPubMed

36.

Reis-Filho JS, Tutt AN (2008) Triple negative tumours: a critical review. Histopathology 52:108–118CrossRefPubMed

37.

Shiu KK, Tan DS, Reis-Filho JS (2008) Development of therapeutic approaches to ‘triple negative’ phenotype breast cancer. Expert Opin Ther Targets 12:1123–1137CrossRefPubMed

38.

Toyama T, Yamashita H, Kondo N et al (2008) Frequently increased epidermal growth factor receptor (EGFR) copy numbers and decreased BRCA1 mRNA expression in Japanese triple-negative breast cancers. BMC Cancer 8:309CrossRefPubMed

39.

Tan DS, Marchio C, Jones RL et al (2008) Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients. Breast Cancer Res Treat 111:27–44CrossRefPubMed

40.

Sanchez-Munoz A, Gallego E, de Luque V et al (2010) Lack of evidence for KRAS oncogenic mutations in triple-negative breast cancer. BMC Cancer 10:136CrossRefPubMed

41.

Bergamaschi A, Kim YH, Wang P et al (2006) Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and gene-expression subtypes of breast cancer. Genes Chromosomes Cancer 45:1033–1040CrossRefPubMed

42.

Jones C, Nonni AV, Fulford L et al (2001) CGH analysis of ductal carcinoma of the breast with basaloid/myoepithelial cell differentiation. Br J Cancer 85:422–427CrossRefPubMed

43.

Korsching E, Packeisen J, Agelopoulos K et al (2002) Cytogenetic alterations and cytokeratin expression patterns in breast cancer: integrating a new model of breast differentiation into cytogenetic pathways of breast carcinogenesis. Lab Invest 82:1525–1533PubMed

44.

Perou CM, Sorlie T, Eisen MB et al (2000) Molecular portraits of human breast tumours. Nature 406:747–752CrossRefPubMed

45.

Bertucci F, Finetti P, Cervera N et al (2008) How basal are triple-negative breast cancers? Int J Cancer 123:236–240CrossRefPubMed

46.

Kim MJ, Ro JY, Ahn SH et al (2006) Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes. Hum Pathol 37:1217–1226CrossRefPubMed

47.

Nielsen TO, Hsu FD, Jensen K et al (2004) Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 10:5367–5374CrossRefPubMed

48.

Rakha EA, Elsheikh SE, Aleskandarany MA et al (2009) Triple-negative breast cancer: distinguishing between basal and nonbasal subtypes. Clin Cancer Res 15:2302–2310CrossRefPubMed

49.

Yamamoto Y, Ibusuki M, Nakano M et al (2009) Clinical significance of basal-like subtype in triple-negative breast cancer. Breast Cancer 16:260–267CrossRefPubMed

50.

Turner N, Tutt A, Ashworth A (2004) Hallmarks of ‘BRCAness’ in sporadic cancers. Nat Rev Cancer 4:814–819CrossRefPubMed

51.

Wooster R, Weber BL (2003) Breast and ovarian cancer. N Engl J Med 348:2339–2347CrossRefPubMed

52.

Linn SC, Van ‘t Veer LJ (2009) Clinical relevance of the triple-negative breast cancer concept: genetic basis and clinical utility of the concept. Eur J Cancer 45(Suppl 1):11–26CrossRefPubMed

53.

Foulkes WD, Brunet JS, Stefansson IM et al (2004) The prognostic implication of the basal-like (cyclin E high/p27 low/p53+/glomeruloid-microvascular-proliferation+) phenotype of BRCA1-related breast cancer. Cancer Res 64:830–835CrossRefPubMed

54.

Crook T, Brooks LA, Crossland S et al (1998) p53 mutation with frequent novel condons but not a mutator phenotype in BRCA1- and BRCA2-associated breast tumours. Oncogene 17:1681–1689CrossRefPubMed

55.

Richardson AL, Wang ZC, De Nicolo A et al (2006) X chromosomal abnormalities in basal-like human breast cancer. Cancer Cell 9:121–132CrossRefPubMed

56.

Tirkkonen M, Johannsson O, Agnarsson BA et al (1997) Distinct somatic genetic changes associated with tumor progression in carriers of BRCA1 and BRCA2 germ-line mutations. Cancer Res 57:1222–1227PubMed

57.

Futreal PA, Liu Q, Shattuck-Eidens D et al (1994) BRCA1 mutations in primary breast and ovarian carcinomas. Science 266:120–122CrossRefPubMed

58.

Turner NC, Reis-Filho JS, Russell AM et al (2007) BRCA1 dysfunction in sporadic basal-like breast cancer. Oncogene 26:2126–2132CrossRefPubMed

59.

Bidard FC, Matthieu MC, Chollet P et al (2008) p53 status and efficacy of primary anthracyclines/alkylating agent-based regimen according to breast cancer molecular classes. Ann Oncol 19:1261–1265CrossRefPubMed

60.

Carey LA, Dees EC, Sawyer L et al (2007) The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 13:2329–2334CrossRefPubMed

61.

Liedtke C, Mazouni C, Hess KR et al (2008) Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 26:1275–1281CrossRefPubMed

62.

Di Leo A, Isola J, Piette F et al (2009) A meta-analysis of phase III trials evaluating the predictive value of HER2 and topoisomerase II alpha in early breast cancer patients treated with CMF or anthracycline-based adjuvant therapy. Cancer Res 69 (abstract 705)

63.

Cheang M, Chia SK, Tu D et al (2009) Anthracyclines in basal breast cancer: the NCIC-CTG trial MA5 comparing adjuvant CMF to CEF. J Clin Oncol 27 (abstract 519)

64.

Hayes DF, Thor AD, Dressler LG et al (2007) HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med 357:1496–1506CrossRefPubMed

65.

Ellis P, Barrett-Lee P, Johnson L et al (2009) Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial. Lancet 373:1681–1692CrossRefPubMed

66.

Bhattacharyya A, Ear US, Koller BH et al (2000) The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin. J Biol Chem 275:23899–23903CrossRefPubMed

67.

Tassone P, Tagliaferri P, Perricelli A et al (2003) BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells. Br J Cancer 88:1285–1291CrossRefPubMed

68.

Silver DP, Richardson AL, Eklund AC et al (2010) Efficacy of neoadjuvant cisplatin in triple-negative breast cancer. J Clin Oncol 28:1145–1153CrossRefPubMed

69.

Byrski T, Gronwald J, Huzarski T et al (2010) Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy. J Clin Oncol 28:375–379CrossRefPubMed

70.

Koshy N, Quispe D, Shi R et al (2010) Cisplatin-gemcitabine therapy in metastatic breast cancer: improved outcome in triple negative breast cancer patients compared to non-triple negative patients. Breast Mar 11 [Epub ahead of print]

71.

http://clinicaltrials.gov/ct2/show/NCT00532727

72.

D’Amours D, Desnoyers S, D’Silva I et al (1999) Poly(ADP-ribosyl)ation reactions in the regulation of nuclear functions. Biochem J 342(Pt 2):249–268CrossRefPubMed

73.

Helleday T, Bryant HE, Schultz N (2005) Poly(ADP-ribose) polymerase (PARP-1) in homologous recombination and as a target for cancer therapy. Cell Cycle 4:1176–1178PubMed

74.

Tutt A RM, Garber JE, Domchek S, et al. (2009) Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced breast cancer. J Clin Oncol 27 (abstract 501)

75.

O’Shaughnessy J OC, Pippen J, Yoffe M et al (2009) Efficacy of BSI-201, a PARP Inhibitor, in combination with gemcitabine/carboplatin in triple negative metastatic breast cancer: results of a phase II study. J Clin Oncol 27 (abstract 3)

76.

http://clinicaltrials.gov/ct2/show/NCT00938652

77.

Dubois EA, Cohen AF (2009) Trabectedin. Br J Clin Pharmacol 68:320–321CrossRefPubMed

78.

Delaloge S TK, Blum J, Gonçalves A et al (2009) Preliminary safety and activity results of trabectedin in a phase II trial dedicated to triple-negative (ER−, PR−, HER2−), HER2+++, or BRCA1/2 germ-line-mutated metastatic breast cancer (MBC) patients (pts). J Clin Oncol 27 (abstract 1010)

79.

Carey LA, Rugo HS, Marcom PK et al (2009) TBCRC 001: EGFR inhibition with cetuximab added to carboplatin in metastatic triple-negative (basal-like) breast cancer. J Clin Oncol 27 (abstract 1009)

80.

Normanno N, Campiglio M, Maiello MR et al (2008) Breast cancer cells with acquired resistance to the EGFR tyrosine kinase inhibitor gefitinib show persistent activation of MAPK signaling. Breast Cancer Res Treat 112:25–33CrossRefPubMed

81.

Normanno N, De Luca A, Maiello MR et al (2006) The MEK/MAPK pathway is involved in the resistance of breast cancer cells to the EGFR tyrosine kinase inhibitor gefitinib. J Cell Physiol 207:420–427CrossRefPubMed

82.

Linderholm BK, Hellborg H, Johansson U et al (2009) Significantly higher levels of vascular endothelial growth factor (VEGF) and shorter survival times for patients with primary operable triple-negative breast cancer. Ann Oncol 20:1639–1646CrossRefPubMed

83.

Ryden L, Jirstrom K, Haglund M et al (2010) Epidermal growth factor receptor and vascular endothelial growth factor receptor 2 are specific biomarkers in triple-negative breast cancer. Results from a controlled randomized trial with long-term follow-up. Breast Cancer Res Treat 120:491–498CrossRefPubMed

84.

Ryan PD, Tung NM, Isakoff SJ et al (2009) Neoadjuvant cisplatin and bevacizumab in triple negative breast cancer (TNBC): Safety and efficacy. J Clin Oncol 27 (abstract 551)

85.

Burstein HJ, Elias AD, Rugo HS et al (2008) Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 26:1810–1816CrossRefPubMed

86.

http://clinicaltrials.gov/ct2/show/NCT00861705

87.

http://clinicaltrials.gov/ct2/show/NCT00528567

88.

Finn RS, Dering J, Ginther C et al (2007) Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/“triple-negative” breast cancer cell lines growing in vitro. Breast Cancer Res Treat 105:319–326CrossRefPubMed

89.

Finn RS, Bengala C, Ibrahim N et al (2009) Phase II trial of dasatinib in triple-negative breast cancer: results of study CA180059. Cancer Res 69 (abstract 3118)

90.

Livasy CA, Karaca G, Nanda R et al (2006) Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol 19:264–271CrossRefPubMed

91.

Le Tourneau C, Dettwiler S, Laurence V et al (2007) 47% pathologic complete response rate to anthracyclines-based associated with high cyclophosphamide doses neoadjuvant chemotherapy in basal-like and triple negative breast cancer patients. Breast Cancer Res Treat 106 (abstract 4010)

92.

Keam B, Im SA, Kim HJ et al (2007) Prognostic impact of clinicopathologic parameters in stage II/III breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy: paradoxical features of the triple negative breast cancer. BMC Cancer 7:203CrossRefPubMed

93.

Toi M, Nakamura S, Kuroi K et al (2008) Phase II study of preoperative sequential FEC and docetaxel predicts of pathological response and disease free survival. Breast Cancer Res Treat 110:531–539CrossRefPubMed

94.

Darb-Esfahani S, Loibl S, Muller BM et al (2009) Identification of biology-based breast cancer types with distinct predictive and prognostic features: role of steroid hormone and HER2 receptor expression in patients treated with neoadjuvant anthracycline/taxane-based chemotherapy. Breast Cancer Res 11:R69CrossRefPubMed

95.

Straver ME, Glas AM, Hannemann J et al (2010) The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer. Breast Cancer Res Treat 119:551–558CrossRefPubMed

96.

Sirohi B, Arnedos M, Popat S et al (2008) Platinum-based chemotherapy in triple-negative breast cancer. Ann Oncol 19:1847–1852CrossRefPubMed

97.

Rouzier R, Perou CM, Symmans WF et al (2005) Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 11:5678–5685CrossRefPubMed

98.

Rody A, Karn T, Solbach C et al (2007) The erbB2+ cluster of the intrinsic gene set predicts tumor response of breast cancer patients receiving neoadjuvant chemotherapy with docetaxel, doxorubicin and cyclophosphamide within the GEPARTRIO trial. Breast 16:235–240CrossRefPubMed

99.

de Ronde JJ, Hannemann J, Halfwerk H et al (2009) Concordance of clinical and molecular breast cancer subtyping in the context of preoperative chemotherapy response. Breast Cancer Res Treat 119:119–126CrossRefPubMed

100.

Chappuis PO, Goffin J, Wong N et al (2002) A significant response to neoadjuvant chemotherapy in BRCA1/2 related breast cancer. J Med Genet 39:608–610CrossRefPubMed

Title: Clinicopathological features and treatment strategy for triple-negative breast cancer
Authors: Yutaka Yamamoto
Hirotaka Iwase
Publication date: 01-08-2010
Publisher: Springer Japan
Published in: International Journal of Clinical Oncology / Issue 4/2010
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI: https://doi.org/10.1007/s10147-010-0106-1

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2010

Endometrial carcinoma: better prognosis for asymptomatic recurrences than for symptomatic cases found by routine follow-up

Third-line gemcitabine monotherapy for platinum-resistant advanced urothelial cancer

Abdominal soft tissue sarcoma: a multicenter retrospective study

Treatment strategy for HER2-positive breast cancer

A prospective, randomized, placebo-controlled trial of zoledronic acid in bony metastatic bladder cancer

A case report of metastatic neuroendocrine carcinoma of the right adrenal gland successfully treated with chemotherapy and surgery

Keynote webinar | Spotlight on antibody–drug conjugates in cancer